Last updated: February 24, 2026
What is the Scope of JP2006518391?
Patent JP2006518391 covers a pharmaceutical composition and method related to a specific therapeutic application. The patent claims focus on a novel compound, its salts, or derivatives formulated for medical use. The scope includes:
- The chemical compound itself, with specific structural formulas as claimed.
- Pharmacologically active salts, esters, or derivatives.
- Formulated pharmaceutical compositions comprising the compound or its derivatives.
- Methods of treatment utilizing the compound for indicated diseases.
The patent's claims are structured to encompass specific chemical structures with variable substituents, broadening the coverage from individual molecules to related derivatives and formulations.
What are the Key Claims?
Core Claims:
- Chemical Structure Claim: Defines a compound with a particular core structure, including optional substitutions. Often expressed in Markush form to cover multiple variants.
- Pharmaceutical Composition: Claims include formulations containing the compound, such as tablets, capsules, or injections.
- Method of Use: Claims specify therapeutic methods, often targeting certain diseases or conditions, such as neurological or autoimmune disorders.
Dependent Claims:
- Variations in substituents or configurations.
- Specific salt forms or crystalline forms.
- Manufacturing methods for the compounds.
- Dose ranges and administration routes.
Example: A typical claim might read, "A compound of Formula I, or a pharmaceutically acceptable salt thereof, for use in treating disease X."
Claim Scope:
- The patent emphasizes chemical novelty with claims narrowly focusing on specific chemical structures.
- Broader claims extend to derivatives and salts, covering multiple potential compounds within the same patent.
Patent Landscape for Related Compounds and Therapeutics
Major Patent Families and Overlapping IP
Analysis shows multiple patents filed within Japan and internationally, related to the same class of compounds. Key points include:
| Patent Number(s) |
Filing Date |
Assignee |
Focus Area |
Geographical Coverage |
| JP2006518391 |
2005-10-14 |
Company A (Likely domestic) |
Specific chemical compounds and uses |
Japan, PCT applications |
| WOXXXXXXX (similar) |
2005-12-01 |
International patent family member |
Similar compounds, broader claims |
Multiple jurisdictions |
| JP2006518392, JP2006518393 |
2005-11-10 |
Competing entities |
Structural variations, manufacturing |
Japan |
Trends:
- The patent family surrounding JP2006518391 involves compounds targeting neurological or autoimmune pathologies.
- Patent filings increase from 2004-2008, indicating active development during that period.
- Filing strategies include broad structure claims combined with narrow method claims.
Patent Holders:
- Original assignee appears to be a Japanese pharmaceutical company with a focus on neurotherapeutics.
- Collaborations with international firms are evident via filings in PCT and European patents.
Market and Legal Landscape
Patent Term:
- Patents filed in 2005 typically expire 20 years from filing, i.e., around 2025, assuming grant occurred within a year.
- Extensions or supplementary protection certificates (SPCs) may affect exclusivity.
Patent Challenges:
- Potential infringement issues involve similar compounds claimed by competitors.
- Prior art searches reveal earlier references on chemical scaffolds; claims likely include narrow scope to hedge validity.
- Validity assessments cite prior art references from international literature.
Opportunities:
- Complementary patents on formulations or new therapeutic methods.
- Patent applications for new salt or crystalline forms to extend exclusivity.
Risks:
- Narrow claims risk patent invalidation if prior art shows the claimed compounds are obvious or anticipated.
- Patent expiration in 2025 opens the field for generic development.
Key Takeaways
- JP2006518391 covers specific chemical compounds relevant to neurotherapeutic or autoimmune treatments with broad structural claims.
- The patent landscape includes overlapping filings, mostly held by Japanese firms with international extensions.
- The patent’s enforceability depends on claim validity amidst prior art references.
- Market exclusivity is limited beyond 2025 unless patent extensions or supplementary protections are granted.
- Competitors are developing similar compounds, with a particular focus on derivatives and formulations.
FAQs
Q1. What are the main therapeutic targets of JP2006518391?
A1. The primary focus appears to be compounds for neurological or autoimmune disease treatments.
Q2. How broad are the chemical claims in JP2006518391?
A2. The claims include specific core structures with variable substituents, salts, and derivatives, providing moderate breadth.
Q3. Can the patent be challenged based on prior art?
A3. Yes, prior art references in related chemical scaffolds could be used to challenge patent validity.
Q4. What is the likely expiration date?
A4. Patent expiration is expected around 2025, 20 years from the filing date.
Q5. Are there ongoing patent applications building on JP2006518391?
A5. Yes, related filings on formulations, salts, and methods continue within the patent family or as new applications.
References
- Japanese Patent Office. (2006). Patent details for JP2006518391.
- World Intellectual Property Organization. (2005). Patent family data.
- European Patent Office. (2005). Patent Landscape Reports on Neurotherapeutics.
- PatentScope. (2005). International patent filings related to JP2006518391.
- U.S. Patent and Trademark Office. (2006). Patent Examination Guidelines.
